구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART123 (Anti-CD123 LV redirected T cells, Anti-CD123 LV redirected T cells (CART123)) Stephan Grupp MD PhD·Acute Myeloid Leukemia (AML) 8 trials |
|---|---|
Overview Program | Anti-CD123 LV redirected T cells (CART123) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia (AML) |
Overview Indication | Acute Myeloid Leukemia (AML) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentivirally transduced anti-CD123-4-1BB-CD3ζ T cells (CART123); and (3) T-cell abla |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | CD19 and contains a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | CD123-targeted CAR T cell (CART123) is promising immunotherapy, but how to improve the complete remission (CR) rate and rescue potential hematopoietic toxicity still need to explore. |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG + AML.. Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). FUS-ERG + AML is rare but has an extremely poor prognosis even with allo-HSCT in r… |
Clinical Safety signal | Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG + AML.. Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). FUS-ERG + AML is rare but has an extremely poor prognosis even with allo-HSCT in r… |
Clinical Program phase | PHASE_1 |
Preclinical Animal (cat.) | Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART123 (Anti-CD123 LV redirected T cells, Anti-CD123 LV redirected T cells (CART123)) Stephan Grupp MD PhD·Acute Myeloid Leukemia (AML) 8 trials |
|---|---|
Overview Program | Anti-CD123 LV redirected T cells (CART123) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia (AML) |
Overview Indication | Acute Myeloid Leukemia (AML) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentivirally transduced anti-CD123-4-1BB-CD3ζ T cells (CART123); and (3) T-cell abla |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | CD19 and contains a high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | CD123-targeted CAR T cell (CART123) is promising immunotherapy, but how to improve the complete remission (CR) rate and rescue potential hematopoietic toxicity still need to explore. |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG + AML.. Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). FUS-ERG + AML is rare but has an extremely poor prognosis even with allo-HSCT in r… |
Clinical Safety signal | Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG + AML.. Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). FUS-ERG + AML is rare but has an extremely poor prognosis even with allo-HSCT in r… |
Clinical Program phase | PHASE_1 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교